HRP20130120T1 - Analozi piridona i piridazona kao gpr119 modulatori - Google Patents
Analozi piridona i piridazona kao gpr119 modulatori Download PDFInfo
- Publication number
- HRP20130120T1 HRP20130120T1 HRP20130120AT HRP20130120T HRP20130120T1 HR P20130120 T1 HRP20130120 T1 HR P20130120T1 HR P20130120A T HRP20130120A T HR P20130120AT HR P20130120 T HRP20130120 T HR P20130120T HR P20130120 T1 HRP20130120 T1 HR P20130120T1
- Authority
- HR
- Croatia
- Prior art keywords
- aryl
- alkyl
- heteroaryl
- cycloalkyl
- heterocyclyl
- Prior art date
Links
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 claims 163
- 125000000217 alkyl group Chemical group 0.000 claims 141
- 125000001072 heteroaryl group Chemical group 0.000 claims 138
- 125000000753 cycloalkyl group Chemical group 0.000 claims 103
- 125000000623 heterocyclic group Chemical group 0.000 claims 101
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 67
- 125000003710 aryl alkyl group Chemical group 0.000 claims 60
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 58
- 229910052739 hydrogen Inorganic materials 0.000 claims 51
- 239000001257 hydrogen Substances 0.000 claims 51
- 125000004093 cyano group Chemical group *C#N 0.000 claims 44
- 125000005843 halogen group Chemical group 0.000 claims 44
- 150000002431 hydrogen Chemical class 0.000 claims 41
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 38
- 125000003342 alkenyl group Chemical group 0.000 claims 37
- 125000001188 haloalkyl group Chemical group 0.000 claims 37
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 35
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 35
- 125000000304 alkynyl group Chemical group 0.000 claims 34
- 125000005842 heteroatom Chemical group 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 19
- 229910052717 sulfur Inorganic materials 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- -1 amino, hydroxy Chemical group 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 10
- 125000004414 alkyl thio group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 5
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 2
- 125000005110 aryl thio group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- ZOLRIOBMWYRUGS-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-5-yl)-4-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]oxypyridin-2-one Chemical compound N1=CC(CCC)=CN=C1N1CCC(OC2=CC(=O)N(C=3C=C4N=C(C)OC4=CC=3)C=C2)CC1 ZOLRIOBMWYRUGS-UHFFFAOYSA-N 0.000 claims 1
- UTQUMWZPEDSNAH-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-6-yl)-4-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]oxypyridin-2-one Chemical compound N1=CC(CCC)=CN=C1N1CCC(OC2=CC(=O)N(C=3C=C4OC(C)=NC4=CC=3)C=C2)CC1 UTQUMWZPEDSNAH-UHFFFAOYSA-N 0.000 claims 1
- DNGFTIKPXNJIBT-UHFFFAOYSA-N 1-(2-propan-2-yl-1,3-benzoxazol-5-yl)-4-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]oxypyridin-2-one Chemical compound N1=CC(CCC)=CN=C1N1CCC(OC2=CC(=O)N(C=3C=C4N=C(OC4=CC=3)C(C)C)C=C2)CC1 DNGFTIKPXNJIBT-UHFFFAOYSA-N 0.000 claims 1
- FNOIIWTWYBZNFY-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-4-[1-(5-iodopyrimidin-2-yl)piperidin-4-yl]oxy-6-oxopyridazine-3-carbonitrile Chemical compound C1=C(Cl)C(Cl)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(I)=CN=2)C(C#N)=N1 FNOIIWTWYBZNFY-UHFFFAOYSA-N 0.000 claims 1
- ZJSNRQKZPQHAFS-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-6-oxo-4-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]oxypyridazine-3-carbonitrile Chemical compound N1=CC(CCC)=CN=C1N1CCC(OC=2C(=NN(C(=O)C=2)C=2C=C(Cl)C(Cl)=CC=2)C#N)CC1 ZJSNRQKZPQHAFS-UHFFFAOYSA-N 0.000 claims 1
- CXZHZHZJDJPJHL-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-6-oxo-4-[1-[5-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl]oxypyridazine-3-carbonitrile Chemical compound N1=CC(C(F)(F)F)=CN=C1N1CCC(OC=2C(=NN(C(=O)C=2)C=2C=C(Cl)C(Cl)=CC=2)C#N)CC1 CXZHZHZJDJPJHL-UHFFFAOYSA-N 0.000 claims 1
- DDJDIHFWRKTLPW-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)-4-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]oxy-6-oxopyridazine-3-carbonitrile Chemical compound FC1=CC(Br)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(Cl)=CN=2)C(C#N)=N1 DDJDIHFWRKTLPW-UHFFFAOYSA-N 0.000 claims 1
- FYRNKUJPCREPGA-UHFFFAOYSA-N 1-(4-bromo-3-fluorophenyl)-4-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]oxy-6-oxopyridazine-3-carbonitrile Chemical compound C1=C(Br)C(F)=CC(N2C(C=C(OC3CCN(CC3)C=3N=CC(Cl)=CN=3)C(C#N)=N2)=O)=C1 FYRNKUJPCREPGA-UHFFFAOYSA-N 0.000 claims 1
- ZTKCFYYPXNYKQS-UHFFFAOYSA-N 1-(4-cyano-3-fluorophenyl)-4-[1-(5-iodopyrimidin-2-yl)piperidin-4-yl]oxy-6-oxopyridazine-3-carbonitrile Chemical compound C1=C(C#N)C(F)=CC(N2C(C=C(OC3CCN(CC3)C=3N=CC(I)=CN=3)C(C#N)=N2)=O)=C1 ZTKCFYYPXNYKQS-UHFFFAOYSA-N 0.000 claims 1
- BGXDSPPKIWTZCM-UHFFFAOYSA-N 1-(4-cyano-3-fluorophenyl)-6-oxo-4-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]oxypyridazine-3-carbonitrile Chemical compound N1=CC(CCC)=CN=C1N1CCC(OC=2C(=NN(C(=O)C=2)C=2C=C(F)C(C#N)=CC=2)C#N)CC1 BGXDSPPKIWTZCM-UHFFFAOYSA-N 0.000 claims 1
- RLJXSSOXMQLDDJ-UHFFFAOYSA-N 1-(4-cyano-3-fluorophenyl)-6-oxo-4-[1-[5-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl]oxypyridazine-3-carbonitrile Chemical compound C1=C(C#N)C(F)=CC(N2C(C=C(OC3CCN(CC3)C=3N=CC(=CN=3)C(F)(F)F)C(C#N)=N2)=O)=C1 RLJXSSOXMQLDDJ-UHFFFAOYSA-N 0.000 claims 1
- NHPKODRMSBRNNL-UHFFFAOYSA-N 1-(4-methylsulfonylphenyl)-6-oxo-4-[1-[5-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl]oxypyridazine-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(=CN=2)C(F)(F)F)C(C#N)=N1 NHPKODRMSBRNNL-UHFFFAOYSA-N 0.000 claims 1
- SYPMUXPBRUFPPP-UHFFFAOYSA-N 1-(6-cyanopyridin-3-yl)-4-[1-(5-iodopyrimidin-2-yl)piperidin-4-yl]oxy-6-oxopyridazine-3-carbonitrile Chemical compound N1=CC(I)=CN=C1N1CCC(OC=2C(=NN(C(=O)C=2)C=2C=NC(=CC=2)C#N)C#N)CC1 SYPMUXPBRUFPPP-UHFFFAOYSA-N 0.000 claims 1
- SIWDJNIVGMMYEZ-UHFFFAOYSA-N 1-(6-cyanopyridin-3-yl)-6-oxo-4-[1-[5-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl]oxypyridazine-3-carbonitrile Chemical compound N1=CC(C(F)(F)F)=CN=C1N1CCC(OC=2C(=NN(C(=O)C=2)C=2C=NC(=CC=2)C#N)C#N)CC1 SIWDJNIVGMMYEZ-UHFFFAOYSA-N 0.000 claims 1
- HULUTEQBGKOKRV-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-5-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]oxypyridazin-3-one Chemical compound N1=CC(CCC)=CN=C1N1CCC(OC2=CC(=O)N(C=3C=C(Cl)C(Cl)=CC=3)N=C2)CC1 HULUTEQBGKOKRV-UHFFFAOYSA-N 0.000 claims 1
- LNIWLXPXHIGJEE-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-5-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]oxypyridazin-3-one Chemical compound N1=CC(CCC)=CN=C1N1CCC(OC2=CC(=O)N(C=3C=CC(=CC=3)S(C)(=O)=O)N=C2)CC1 LNIWLXPXHIGJEE-UHFFFAOYSA-N 0.000 claims 1
- DAUWKSLHXXOBIL-GHTZIAJQSA-N 4-[(2s,4r)-2-methyl-1-(5-propylpyrimidin-2-yl)piperidin-4-yl]oxy-1-(4-methylsulfonylphenyl)pyridin-2-one Chemical compound N1=CC(CCC)=CN=C1N1[C@@H](C)C[C@H](OC2=CC(=O)N(C=3C=CC(=CC=3)S(C)(=O)=O)C=C2)CC1 DAUWKSLHXXOBIL-GHTZIAJQSA-N 0.000 claims 1
- KMSLMPXQCNNBIW-UHFFFAOYSA-N 4-[1-(5-bromopyrimidin-2-yl)piperidin-4-yl]oxy-1-(4-cyano-3-fluorophenyl)-6-oxopyridazine-3-carbonitrile Chemical compound C1=C(C#N)C(F)=CC(N2C(C=C(OC3CCN(CC3)C=3N=CC(Br)=CN=3)C(C#N)=N2)=O)=C1 KMSLMPXQCNNBIW-UHFFFAOYSA-N 0.000 claims 1
- DNBBZWRLTMJLIU-UHFFFAOYSA-N 4-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]oxy-1-(3,4-dichlorophenyl)-6-oxopyridazine-3-carbonitrile Chemical compound N1=CC(Cl)=CN=C1N1CCC(OC=2C(=NN(C(=O)C=2)C=2C=C(Cl)C(Cl)=CC=2)C#N)CC1 DNBBZWRLTMJLIU-UHFFFAOYSA-N 0.000 claims 1
- QEPMGKHRJDRKRA-UHFFFAOYSA-N 4-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]oxy-1-(4-methylsulfonylphenyl)-6-oxopyridazine-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(Cl)=CN=2)C(C#N)=N1 QEPMGKHRJDRKRA-UHFFFAOYSA-N 0.000 claims 1
- CEFBJQIWTVXQOY-UHFFFAOYSA-N 4-[1-(5-cyanopyrimidin-2-yl)piperidin-4-yl]oxy-1-(4-methylsulfonylphenyl)-6-oxopyridazine-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(=CN=2)C#N)C(C#N)=N1 CEFBJQIWTVXQOY-UHFFFAOYSA-N 0.000 claims 1
- VPMFWUORLQIHSU-UHFFFAOYSA-N 4-[1-(5-cyclopropylpyrimidin-2-yl)piperidin-4-yl]oxy-1-(3,4-dichlorophenyl)-6-oxopyridazine-3-carbonitrile Chemical compound C1=C(Cl)C(Cl)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(=CN=2)C2CC2)C(C#N)=N1 VPMFWUORLQIHSU-UHFFFAOYSA-N 0.000 claims 1
- MJRDPBMJYROUDG-UHFFFAOYSA-N 4-[1-(5-iodopyrimidin-2-yl)piperidin-4-yl]oxy-1-(4-methylsulfonylphenyl)-6-oxopyridazine-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(I)=CN=2)C(C#N)=N1 MJRDPBMJYROUDG-UHFFFAOYSA-N 0.000 claims 1
- HNNCJYMFLNBDFO-UHFFFAOYSA-N 4-[1-[5-(difluoromethoxy)pyrimidin-2-yl]piperidin-4-yl]oxy-1-(4-methylsulfonylphenyl)-6-oxopyridazine-3-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(OC(F)F)=CN=2)C(C#N)=N1 HNNCJYMFLNBDFO-UHFFFAOYSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- YBXXGIAOCOLCOU-UHFFFAOYSA-N 5-[1-(5-acetylpyrimidin-2-yl)piperidin-4-yl]oxy-2-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound N1=CC(C(=O)C)=CN=C1N1CCC(OC2=CC(=O)N(C=3C=CC(=CC=3)S(C)(=O)=O)N=C2)CC1 YBXXGIAOCOLCOU-UHFFFAOYSA-N 0.000 claims 1
- OLRSIDWVXJFEEO-UHFFFAOYSA-N 5-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]oxy-6-(hydroxymethyl)-2-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(Cl)=CN=2)C(CO)=N1 OLRSIDWVXJFEEO-UHFFFAOYSA-N 0.000 claims 1
- ODXRUCYUIVSMNG-UHFFFAOYSA-N 5-[1-(5-cyclopropylpyrimidin-2-yl)piperidin-4-yl]oxy-2-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(=CN=2)C2CC2)C=N1 ODXRUCYUIVSMNG-UHFFFAOYSA-N 0.000 claims 1
- OVYUTRBQLZNCKS-UHFFFAOYSA-N 5-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]oxy-2-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound N1=CC(CC)=CN=C1N1CCC(OC2=CC(=O)N(C=3C=CC(=CC=3)S(C)(=O)=O)N=C2)CC1 OVYUTRBQLZNCKS-UHFFFAOYSA-N 0.000 claims 1
- NHXNXSZZKICVPU-UHFFFAOYSA-N 6-(hydroxymethyl)-5-[1-(5-iodopyrimidin-2-yl)piperidin-4-yl]oxy-2-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(=O)C=C(OC2CCN(CC2)C=2N=CC(I)=CN=2)C(CO)=N1 NHXNXSZZKICVPU-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- 102100034013 Gamma-glutamyl phosphate reductase Human genes 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 108010010369 HIV Protease Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- JJLKTTCRRLHVGL-UHFFFAOYSA-L [acetyloxy(dibutyl)stannyl] acetate Chemical compound CC([O-])=O.CC([O-])=O.CCCC[Sn+2]CCCC JJLKTTCRRLHVGL-UHFFFAOYSA-L 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims 1
- 125000005325 aryloxy aryl group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 1
- 125000005368 heteroarylthio group Chemical group 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- MQJITIGDPCCLDU-UHFFFAOYSA-N methyl 1-(3,4-dichlorophenyl)-4-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]oxy-6-oxopyridazine-3-carboxylate Chemical compound O=C1C=C(OC2CCN(CC2)C(=O)OC(C)(C)C)C(C(=O)OC)=NN1C1=CC=C(Cl)C(Cl)=C1 MQJITIGDPCCLDU-UHFFFAOYSA-N 0.000 claims 1
- AFTKQMWKIBEUJR-UHFFFAOYSA-N methyl 1-(4-bromo-2-fluorophenyl)-4-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]oxy-6-oxopyridazine-3-carboxylate Chemical compound O=C1C=C(OC2CCN(CC2)C(=O)OC(C)(C)C)C(C(=O)OC)=NN1C1=CC=C(Br)C=C1F AFTKQMWKIBEUJR-UHFFFAOYSA-N 0.000 claims 1
- CELDTPDTZVSCII-UHFFFAOYSA-N methyl 1-(4-bromo-3-fluorophenyl)-4-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]oxy-6-oxopyridazine-3-carboxylate Chemical compound O=C1C=C(OC2CCN(CC2)C(=O)OC(C)(C)C)C(C(=O)OC)=NN1C1=CC=C(Br)C(F)=C1 CELDTPDTZVSCII-UHFFFAOYSA-N 0.000 claims 1
- SLGBFOWTQHIJRF-UHFFFAOYSA-N methyl 1-(4-cyano-3-fluorophenyl)-4-[1-(5-cyclopropylpyrimidin-2-yl)piperidin-4-yl]oxy-6-oxopyridazine-3-carboxylate Chemical compound O=C1C=C(OC2CCN(CC2)C=2N=CC(=CN=2)C2CC2)C(C(=O)OC)=NN1C1=CC=C(C#N)C(F)=C1 SLGBFOWTQHIJRF-UHFFFAOYSA-N 0.000 claims 1
- DCNVSQXLNAHFAQ-UHFFFAOYSA-N methyl 1-(4-cyano-3-fluorophenyl)-4-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]oxy-6-oxopyridazine-3-carboxylate Chemical compound O=C1C=C(OC2CCN(CC2)C(=O)OC(C)(C)C)C(C(=O)OC)=NN1C1=CC=C(C#N)C(F)=C1 DCNVSQXLNAHFAQ-UHFFFAOYSA-N 0.000 claims 1
- HYBNUZOBDYVJED-UHFFFAOYSA-N methyl 1-(4-cyano-3-fluorophenyl)-6-oxo-4-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]oxypyridazine-3-carboxylate Chemical compound N1=CC(CCC)=CN=C1N1CCC(OC=2C(=NN(C(=O)C=2)C=2C=C(F)C(C#N)=CC=2)C(=O)OC)CC1 HYBNUZOBDYVJED-UHFFFAOYSA-N 0.000 claims 1
- UOGQMLHJEKQHBF-UHFFFAOYSA-N methyl 1-(6-cyanopyridin-3-yl)-4-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]oxy-6-oxopyridazine-3-carboxylate Chemical compound O=C1C=C(OC2CCN(CC2)C(=O)OC(C)(C)C)C(C(=O)OC)=NN1C1=CC=C(C#N)N=C1 UOGQMLHJEKQHBF-UHFFFAOYSA-N 0.000 claims 1
- XHLFLSLERBBNAO-UHFFFAOYSA-N methyl 4-[1-(5-bromopyrimidin-2-yl)piperidin-4-yl]oxy-1-(4-cyano-3-fluorophenyl)-6-oxopyridazine-3-carboxylate Chemical compound O=C1C=C(OC2CCN(CC2)C=2N=CC(Br)=CN=2)C(C(=O)OC)=NN1C1=CC=C(C#N)C(F)=C1 XHLFLSLERBBNAO-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- CSTCILFMBXQPJD-UHFFFAOYSA-N propan-2-yl 4-[3-cyano-1-(4-cyano-3-fluorophenyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(=O)N(C=2C=C(F)C(C#N)=CC=2)N=C1C#N CSTCILFMBXQPJD-UHFFFAOYSA-N 0.000 claims 1
- QLFONIBKTHMTTP-UHFFFAOYSA-N propan-2-yl 4-[3-cyano-1-(4-methylsulfonylphenyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(=O)N(C=2C=CC(=CC=2)S(C)(=O)=O)N=C1C#N QLFONIBKTHMTTP-UHFFFAOYSA-N 0.000 claims 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- WJJJLOIYUKJUPY-FUHWJXTLSA-N tert-butyl (2S,4R)-2-methyl-4-[1-(4-methylsulfonylphenyl)-2-oxopyridin-4-yl]oxypiperidine-1-carboxylate Chemical compound C[C@@H]1N(CC[C@H](C1)OC1=CC(N(C=C1)C1=CC=C(C=C1)S(=O)(=O)C)=O)C(=O)OC(C)(C)C WJJJLOIYUKJUPY-FUHWJXTLSA-N 0.000 claims 1
- LUIXGNGNSSPHFL-AUUYWEPGSA-N tert-butyl (3R,4R)-4-[5-chloro-1-(4-cyano-3-fluorophenyl)-2-oxopyridin-4-yl]oxy-3-methylpiperidine-1-carboxylate Chemical compound ClC=1C(=CC(N(C=1)C1=CC(=C(C=C1)C#N)F)=O)O[C@H]1[C@@H](CN(CC1)C(=O)OC(C)(C)C)C LUIXGNGNSSPHFL-AUUYWEPGSA-N 0.000 claims 1
- FUGDVSJDCRANNE-UHFFFAOYSA-N tert-butyl 4-[1-(3,4-dichlorophenyl)-3-(hydroxymethyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=C(Cl)C(Cl)=CC=2)N=C1CO FUGDVSJDCRANNE-UHFFFAOYSA-N 0.000 claims 1
- UXHILQKQEWHAQW-UHFFFAOYSA-N tert-butyl 4-[1-(3,4-dichlorophenyl)-3-(methylcarbamoyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound O=C1C=C(OC2CCN(CC2)C(=O)OC(C)(C)C)C(C(=O)NC)=NN1C1=CC=C(Cl)C(Cl)=C1 UXHILQKQEWHAQW-UHFFFAOYSA-N 0.000 claims 1
- UYTNZSDSABMCHU-UHFFFAOYSA-N tert-butyl 4-[1-(4-bromo-2-fluorophenyl)-3-cyano-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C(=CC(Br)=CC=2)F)N=C1C#N UYTNZSDSABMCHU-UHFFFAOYSA-N 0.000 claims 1
- SZNLDAZJQJQFCI-UHFFFAOYSA-N tert-butyl 4-[1-(4-bromo-3-fluorophenyl)-3-cyano-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=C(F)C(Br)=CC=2)N=C1C#N SZNLDAZJQJQFCI-UHFFFAOYSA-N 0.000 claims 1
- OPTVONFAMRBUCB-UHFFFAOYSA-N tert-butyl 4-[1-(4-cyano-3-fluorophenyl)-3-(hydroxymethyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=C(F)C(C#N)=CC=2)N=C1CO OPTVONFAMRBUCB-UHFFFAOYSA-N 0.000 claims 1
- IWDZSBFNNDKZKC-UHFFFAOYSA-N tert-butyl 4-[1-(4-methylsulfonylphenyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=CC(=CC=2)S(C)(=O)=O)N=C1 IWDZSBFNNDKZKC-UHFFFAOYSA-N 0.000 claims 1
- JYTJDHKQPSVOHF-UHFFFAOYSA-N tert-butyl 4-[1-[(4-methoxyphenyl)methyl]-6-oxo-3-phenylpyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C=C(OC2CCN(CC2)C(=O)OC(C)(C)C)C(C=2C=CC=CC=2)=N1 JYTJDHKQPSVOHF-UHFFFAOYSA-N 0.000 claims 1
- LYRTVNUGHSOQNJ-UHFFFAOYSA-N tert-butyl 4-[1-[(4-methoxyphenyl)methyl]-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C=C(OC2CCN(CC2)C(=O)OC(C)(C)C)C=N1 LYRTVNUGHSOQNJ-UHFFFAOYSA-N 0.000 claims 1
- ZHKCHUVVMYBSFO-UHFFFAOYSA-N tert-butyl 4-[3-amino-1-(3,4-dichlorophenyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=C(Cl)C(Cl)=CC=2)N=C1N ZHKCHUVVMYBSFO-UHFFFAOYSA-N 0.000 claims 1
- WIELFKWIAJKOFN-UHFFFAOYSA-N tert-butyl 4-[3-carbamoyl-1-(3,4-dichlorophenyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=C(Cl)C(Cl)=CC=2)N=C1C(N)=O WIELFKWIAJKOFN-UHFFFAOYSA-N 0.000 claims 1
- GUEBHVFQESUDAR-UHFFFAOYSA-N tert-butyl 4-[3-chloro-1-(3,4-dichlorophenyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=C(Cl)C(Cl)=CC=2)N=C1Cl GUEBHVFQESUDAR-UHFFFAOYSA-N 0.000 claims 1
- CHRXBUUZORBWNY-UHFFFAOYSA-N tert-butyl 4-[3-cyano-1-(3,4-dichlorophenyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=C(Cl)C(Cl)=CC=2)N=C1C#N CHRXBUUZORBWNY-UHFFFAOYSA-N 0.000 claims 1
- NGDNEFQFWZESLM-UHFFFAOYSA-N tert-butyl 4-[3-cyano-1-(4-cyano-3-fluorophenyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=C(F)C(C#N)=CC=2)N=C1C#N NGDNEFQFWZESLM-UHFFFAOYSA-N 0.000 claims 1
- YZGVNJPJZKQJBH-UHFFFAOYSA-N tert-butyl 4-[3-cyano-1-(4-methylsulfonylphenyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=CC(=CC=2)S(C)(=O)=O)N=C1C#N YZGVNJPJZKQJBH-UHFFFAOYSA-N 0.000 claims 1
- LGOJGAGDDCUEAQ-UHFFFAOYSA-N tert-butyl 4-[3-cyano-1-(4-nitrophenyl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=CC(=CC=2)[N+]([O-])=O)N=C1C#N LGOJGAGDDCUEAQ-UHFFFAOYSA-N 0.000 claims 1
- ARAXXVZKAZMBOU-UHFFFAOYSA-N tert-butyl 4-[3-cyano-1-(6-cyanopyridin-3-yl)-6-oxopyridazin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(=O)N(C=2C=NC(=CC=2)C#N)N=C1C#N ARAXXVZKAZMBOU-UHFFFAOYSA-N 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Claims (14)
1. Spoj formule I:
[image]
ili enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, gdje:
Z je CH ili N;
R1 je aril, arilalkil ili heteroaril, od kojih bilo koji može biti po izboru supstituiran s jednim ili više R6;
R2 je cikloalkil, aril, heteroaril, heterociklil, -S(O)2R5, -C(=O)NR3R5, -C(=O)R5 ili -C(=O)OR5, gdje cikloalkil, aril, heteroaril i heterociklil svaki može biti po izboru supstituiran s jednim ili više R6;
R3 je vodik, alkil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil ili heterociklilalkil, gdje heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki može sadržavati 1-4 heteroatoma izabrana između N, O i S;
R5 je alkil, alkenil, aril, cikloalkil, heteroaril ili heterociklil, od kojih svaki može po izboru biti supstituiran s jednim ili više R6;
R6, svaki put kad se pojavljuje, je nezavisno izabran između alkil, aril, alkenil, alkinil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, -OCF3, -OCHF2, -OR10, -OH, -SH, -SR10, -S(O)3H, -P(O)3H2, -C(=O)NR9R9, -NR9R9, -S(O)2NR9R9, -NR9S(O)2CF3, -C(=O)NR9S(O)2R9, -S(O)2NR9C(=O)OR9, -S(O)2NR9C(=O)NR9R9, -C(=O)NR9S(O)2CF3, -C(=O)R10, -NR9C(=O)H, -NR9C(=O)R10, -OC(=O)R10,- C(=NR14)NR9R9, -NHC(=NR14)NR14R14, -S(=O)R10, -S(O)2R10, =O, -NR9C(=O)OR8 i -NR9S(O2)R8, gdje alkil, alkenil, alkinil, aril, cikloalkil, cikloalkilalkil,
heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R9a;
R8, svaki put kad se pojavljuje, je nezavisno izabran iz grupe koja obuhvaća alkil, aril, cikloalkil, heteroaril i heterociklil, od kojih svaki može po izboru biti supstituiran s jednim ili više R8a;
R8a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, arilalkil, alkenil, alkinil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R14, -S(O)2NR14C(=O)OR14, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14, =O, -NR14C(=O)OR14 i -NR14S(O2)R14;
R9, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, alkenil, alkinil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R9a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, alkenil, alkinil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R10,-S(O)2NR14C(=O)OR10, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14, =O i arilalkil;
R10, svaki put kad se pojavljuje, je nezavisno izabran između alkil, alkenil, alkinil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R10a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, alkenil, alkinil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C (=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R9, -S(O)2NR14(=O)OR9, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14 -NR14C(=O)OR14, -NR14S(O2)R14 i arilalkil;
R14, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, aril, cikloalkil, heteroaril i heterociklil;
R21 je vodik, alkil, haloalkil, hidroksialkil, aril, cikloalkil, halo, -CN, -C(=O)OH, -C(=O)OR10, -OCF3, -OCHF2, -OR10, -OH, -C(=O)NR9R9, -C(=O)R10 ili -OC(=O)R10;
T1 je vodik, halo, alkil, aril, alkenil ili alkinil, gdje alkil, aril, alkenil i alkinil mogu po izboru biti supstituirani s jednim ili više R6;
T2 je vodik, alkil, aril, alkenil ili alkinil, gdje alkil, aril, alkenil i alkinil mogu po izboru biti supstituirani s jednim ili više R6;
T3 je vodik, alkil, aril, alkenil ili alkinil, gdje alkil, aril, alkenil i alkinil mogu po izboru biti supstituirani s jednim ili više R6; i
T4 je vodik, halo, alkil, aril, alkenil ili alkinil, gdje alkil, aril, alkenil i alkinil mogu po izboru biti supstituirani s jednim ili više R6; uz uvjet da kada Z je CH i R1 je 5-eročlani do 6-eročlani aril ili heteroaril, T1, T2, T3, i T4 ne mogu svi biti vodik;
pojam "alkil", kako se ovdje koristi, odnosi se i razgranate i ravnolančane zasićene alifatske ugljikovodične skupine koje sadrže 1 do 10 ugljika u normalnom lancu, i po izboru je supstituiran s od 1 do 4 supstituenta izabrana između F, Br, Cl, I, CF3, alkil, alkoksi, aril, ariloksi, aril ili diaril, arilalkil, arilalkiloksi, alkenil, cikloalkil, cikloalkilalkil, cikloalkilalkiloksi, amino, hidroksi, hidroksialkil, acil, heteroaril, heteroariloksi, heteroarilalkil, heteroarilalkoksi, ariloksialkil, alkiltio, arilalkiltio, ariloksiaril, alkilamido, alkanoilamino, arilkarbonilamino, nitro, cijano, tiol, haloalkil, trihaloalkil, i/ili alkiltio;
pojam "alkenil", kako se ovdje koristi, odnosi se na ravne ili razgranate lančane radikale s 2 do 12 ugljika u normalnom lancu, koji sadrži jednu do šest dvostrukih veza u normalnom lancu, i po izboru je supstituiran s 1 do 4 supstituenta izabrana između halogen, haloalkil, alkil, alkoksi, alkenil, alkinil, aril, arilalkil, cikloalkil, amino, hidroksi, heteroaril, cikloheteroalkil, alkanoilamino, alkilamido, arilkarbonil-amino, nitro, cijano, tiol, alkiltio, i/ili bilo koji od alkil supstituenata ovdje navedenih;
pojam "alkinil", kako se ovdje koristi, odnosi se na ravne ili razgranate lančane radikale s 2 do 12 ugljika u normalnom lancu, koji uključuje jednu trostruku vezu u normalnom lancu, i po izboru je supstituiran s 1 do 4 supstituenta izabrana između halogen, haloalkil, alkil, alkoksi, alkenil, alkinil, aril, arilalkil, cikloalkil, amino, heteroaril, cikloheteroalkil, hidroksi, alkanoilamino, alkilamido, arilkarbonilamino, nitro, cijano, tiol, i/ili alkiltio, i/ili bilo koji od alkil supstituenata ovdje navedenih;
pojam "cikloalkil", kako se ovdje koristi, odnosi se na zasićene ili djelomično nezasićene (sadrži 1 ili 2 dvostruke veze) cikličke ugljikovodične skupine koje sadrže 1 do 3 prstena koji sadrže ukupno 3 do 15 ugljika koji formiraju prsten i koji mogu biti fuzionirani za 1 ili 2 aromatska prstena, halogen, alkil, alkoksi, hidroksi, aril, ariloksi, arilalkil, cikloalkil, alkilamido, alkanoilamino, okso, acil, arilkarbonilamino, amino, nitro, cijano, tiol, i/ili alkiltio, i/ili bilo koji supstituent za alkil;
pojam "aril", kako se ovdje koristi, odnosi se na monocikličke i bicikličke aromatske skupine koje sadrže 6 do 10 ugljika u prstenu i po izboru mogu uključivati 1 do 3 dodatna prstena fuzionirana za karbociklički prsten ili heterociklički prsten, i mogu po izboru biti supstituirane preko dostupnih atoma ugljika s 1, 2, ili 3 supstituenta izabrana između halo, haloalkil, alkil, alkoksi, haloalkoksi, alkenil, trifluorometil, trifluorometoksi, alkinil, cikloalkil-alkil, cikloheteroalkil, cikloheteroalkilalkil, aril, heteroaril, arilalkil, ariloksi, ariloksialkil, arilalkoksi, ariltio, arilazo, heteroarilalkil, heteroarilalkenil, heteroarilheteroaril, heteroariloksi, hidroksi, nitro, cijano, amino, supstituirani amino gdje amino obuhvaća 1 ili 2 supstituenta (koji su alkil, aril, ili bilo koji drugi od arilnih spojeva spomenutih u definicijama), tiol, alkiltio, ariltio, heteroariltio, ariltioalkil, alkoksiariltio, alkilkarbonil, arilkarbonil, alkilaminokarbonil, arilaminokarbonil, alkoksikarbonil, aminokarbonil, alkilkarboniloksi, arilkarboniloksi, alkilkarbonilamino, arilkarbonilamino, arilsulfinil, arilsulfinilalkil, arilsulfonilamino, ili arilsulfonaminokarbonil, i/ili bilo koji od alkil supstituenata ovdje navedenih;
pojam "amino", kako se ovdje koristi, odnosi se na amin koji može biti supstituiran s jednim ili dva supstituenta koji mogu biti jednaki ili različiti i izabrani između alkil, aril, arilalkil, heteroaril, heteroarilalkil, cikloheteroalkil, cikloheteroalkilalkil, cikloalkil, cikloalkilalkil, haloalkil, hidroksialkil, alkoksialkil, ili tioalkil, amino supstituenti mogu biti uzeti zajedno s atomom dušika za koji su spojeni da formiraju 1-pirolidinil, 1-piperidinil, 1-azepinil, 4-morfolinil, 4-tiamorfolinil, 1-piperazinil, 4-alkil-1-piperazinil, 4-arilalkil-1-piperazinil, 4-diarilalkil-1-piperazinil, 1-pirolidinil, 1-piperidinil, ili 1-azepinil, po izboru supstituiran s alkil, alkoksi, alkiltio, halo, trifluorometil, ili hidroksi;
pojam "heterociklil", kako se ovdje koristi, odnosi se na stabilni 4-eročlani do 14-eročlani monociklički, biciklički ili triciklički heterociklički prsten koji je zasićeni ili djelomično nezasićeni i koji se sastoji od atoma ugljika i 1, 2, 3, ili 4 heteroatoma nezavisno izabrana iz grupe koja obuhvaća N, NH, O i S i uključujući bilo koju bicikličku skupinu u kojoj je bilo koji od gore definiranih heterocikličkih prstenova fuzioniran za prsten benzena, spomenuti heteroatomi dušika i sumpora su po izboru oksidirani, heterociklički prstenovi mogu biti supstituirani na ugljiku ili na dušiku;
pojam "heteroaril", kako se ovdje koristi, odnosi se na stabilni 5-eročlani do 7-eročlani monociklički ili biciklički ili 7-eročlani do 10-eročlani biciklički heterociklički aromatski prsten koji sadrži atome ugljika i od 1 to 4 heteroatoma nezavisno izabrana između N, O i S.
2. Spoj, enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, gdje spoj formule I je Spoj formule II(y):
[image]
gdje su Z, R1, R2, R21, T3 i T4 definirani kao u zahtjevu 1.
3. Spoj, enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, gdje spoj formule I je Spoj formule II(z):
[image]
gdje su Z, R1, R2 i R21 definirani kao u zahtjevu 1.
4. Spoj, enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, gdje:
Z je CH ili N;
R1 je aril, arilalkil ili heteroaril, od kojih bilo koji može biti po izboru supstituiran s jednim ili više R6;
R2 je cikloalkil, aril, heteroaril, heterociklil, -S(O)2R5, -C(=O)R5 ili -C(=O)OR5, gdje cikloalkil, aril, heteroaril i heterociklil svaki može biti po izboru supstituiran s jednim ili više R6;
R5 je alkil, alkenil, aril, cikloalkil, heteroaril ili heterociklil, od kojih svaki može po izboru biti supstituiran s jednim ili više R6;
R6, svaki put kad se pojavljuje, je nezavisno izabran između alkil, aril, alkenil, alkinil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, -OCF3, -OCHF2, -OR10, -OH, -SH, -SR10, -S(O)3H, -P(O)3H2, -C(=O)NR9R9, -NR9R9, -S(O)2NR9R9, -NR9S(O)2CF3, -C(=O)NR9S(O)2R9, -S(O)2NR9C(=O)OR9, -S(O)2NR9C(=O)NR9R9, -C(=O)NR9S(O)2CF3, -C(=O)R10, -NR9C(=O)H, -NR9C(=O)R10, -OC(=O)R10, -C(=NR14)NR9R9, -NHC(=NR14)NR14R14, -S(=O)R10, -S(O)2R10 i =O, gdje alkil, alkenil, alkinil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R9a;
R8a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, arilalkil, alkenil, alkinil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR4, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O2)R14, -S(O)2NR14C(=O)OR14, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14, =O, -NR14C(=O)OR14 i -NR14S(O2)R14;
R9, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, alkenil, alkinil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R9a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, alkenil, alkinil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2,- OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R10, -S(O)2NR14C(=O)OR10, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14 -NR14S(O2)R14, =O i arilalkil;
R10, svaki put kad se pojavljuje, je nezavisno izabran između alkil, alkenil, alkinil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R10a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, alkenil, alkinil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2 -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)CF3, -C(=O)NR14S(O)2R9, -S(O)2NR14C(=O)OR9, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(-O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14 i arilalkil;
R14, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, aril, cikloalkil, heteroaril i heterociklil;
R21 je vodik, alkil, haloalkil, hidroksialkil, aril, cikloalkil, halo, -CN, -C(=O)OH, -C(=O)OR10, -OCF3, -OR10, -OH, -C(=O)NR9R9, -C(=O)R10 ili -OC(=O)R10;
T1 je vodik, alkil, aril, alkenil ili alkinil, gdje alkil, aril, alkenil i alkinil mogu po izboru biti supstituirani s jednim ili više R6;
T2 je vodik, alkil, aril, alkenil ili alkinil, gdje alkil, aril, alkenil i alkinil mogu po izboru biti supstituirani s jednim ili više R6;
T3 je vodik, alkil, aril, alkenil ili alkinil, gdje alkil, aril, alkenil i alkinil mogu po izboru biti supstituirani s jednim ili više R6; and
T4 je vodik, alkil, aril, alkenil ili alkinil, gdje alkil, aril, alkenil i alkinil mogu po izboru biti supstituirani s jednim ili više R6.
5. Spoj, enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, gdje:
Z je CH ili N;
R1 je aril, arilalkil ili heteroaril, od kojih bilo koji može biti po izboru supstituiran s jednim ili više R6;
R2 je cikloalkil, aril, heteroaril, heterociklil, -C(=O)R5 ili -C(=O)OR5, gdje cikloalkil, aril, heteroaril i heterociklil svaki može biti po izboru supstituiran s jednim ili više R6;
R5 je alkil, aril, cikloalkil, heteroaril ili heterociklil, od kojih svaki može po izboru biti supstituiran s jednim ili više R6;
R6, svaki put kad se pojavljuje, je nezavisno izabran između alkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, -OCF3, -OCHF2, -OR10, -OH, -SH, -SR10, -S(O)3H, -P(O)3H2, -C(=O)NR9R9, -NR9R9, -S(O)2NR9R9, -NR9S(O)2CF3, -C(=O)NR9S(O)2R9, -S(O)2NR9C(=O)OR9, -S(O)2NR9C(=O)NR9R9, -C(=O)NR9S(O)2CF3, -C(=O)R10, -NR9C(=O)H, -NR9C(=O)R10, -OC(=O)R10, -C(=NR14)NR9R9, -NHC(=NR14)NR14R14, -S(=O)R10, -S(O)2R10 i =O, gdje alkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R9a;
R8a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, arilalkil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R14, -S(O)2NR14C(=O)OR14, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3. -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14, =O, -NR14C(=O)OR14 i -NR14S(O2)R14;
R9, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, alkoksi, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R9a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R10, -S(O)2NR14C(=O)OR10, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14 -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14, =O i arilalkil;
R10, svaki put kad se pojavljuje, je nezavisno izabran između alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R10a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R9, -S(O)2NR14C(=O)OR9, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14 i arilalkil;
R14, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, aril, cikloalkil, heteroaril i heterociklil;
R21 je vodik, alkil, haloalkil, hidroksialkil, aril, cikloalkil, halo, -CN, -C(=O)OH, -C(=O)OR10, -OCF3, -OR10, -OH, -C(=O)NR9R9 ili -C(=O)R10;
T1 je vodik, alkil ili aril, gdje alkil ili aril mogu po izboru biti supstituirani s jednim ili više R6;
T2 je vodik, alkil ili aril, gdje alkil ili aril mogu po izboru biti supstituirani s jednim ili više R6;
T3 je vodik, alkil ili aril, gdje alkil ili aril mogu po izboru biti supstituirani s jednim ili više R6; i
T4 je vodik, alkil ili aril, gdje alkil ili aril mogu po izboru biti supstituirani s jednim ili više R6.
6. Spoj, enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, gdje:
Z je CH ili N;
R1 je aril, arilalkil ili heteroaril, od kojih bilo koji može biti po izboru supstituiran s jednim ili više R6;
R2 je aril, heteroaril, heterociklil, -C(=O)R5 ili -C(=O)OR5, gdje aril, heteroaril i heterociklil može svaki biti po izboru supstituiran s jednim ili više R6;
R5 je alkil, aril, cikloalkil ili heteroaril, od kojih svaki može po izboru biti supstituiran s jednim ili više R6;
R6, svaki put kad se pojavljuje, je nezavisno izabran između alkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, -OCF3, -OCHF2, -OR10, -OH, -SH, -SR10, -C(=O)NR9R9, -NR9R9, -S(O)2NR9R9, -NR9S(O)2CF3, -C(=O)NR9S(O)2R9, -S(O)2NR9C(=O)OR9, -S(O)2NR9C(=O)NR9R9, -C(=O)NR9S(O)2CF3, -C(=O)R10, -NR9C(=O)H, -NR9C(=O)R10, -OC(=O)R10, -C(=NR14)NR9R9, -NHC(=NR14)NR14R14, -S(=O)R’°, -S(O)2R10 i =O, gdje alkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R9a;
R8a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, arilalkil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R14, -S(O)2NR14C(=O)OR14, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(O)R14, -S(O)2R14, =O, -NR14C(=O)OR14 i -NR14S(O2)R14;
R9, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril, heteroarilalkil, heterociklil i heterociklilalkil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R9a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, NR14S(O)2CF3, -C(=O)NR14S(O)2R10, -S(O)2NR14C(=O)OR10, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14 -NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14, =O i arilalkil;
R10, svaki put kad se pojavljuje, je nezavisno izabran između alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil i heterociklil, gdje cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil i heterociklil može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril, heteroarilalkil i heterociklil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R10a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R9, -S(O)2NR14C(=O)OR9, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14 i arilalkil;
R14, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, aril, cikloalkil i heteroaril;
R21 je vodik, alkil, haloalkil, hidroksialkil, aril, cikloalkil, halo, -CN, -C(=O)OH, -C(=O)OR10, -OR10, -C(=O)NR9R9 ili -C(=O)R10;
T1 je vodik ili alkil, gdje alkil može po izboru biti supstituiran s jednim ili više R6;
T2 je vodik ili alkil, gdje alkil može po izboru biti supstituiran s jednim ili više R6;
T3 je vodik, alkil ili aril, gdje alkil ili aril mogu po izboru biti supstituirani s jednim ili više R6; i
T4 je vodik ili alkil, gdje alkil može po izboru biti supstituiran s jednim ili više R6.
7. Spoj, enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, gdje:
Z je CH ili N;
R1 je aril, arilalkil ili heteroaril, od kojih bilo koji može biti po izboru supstituiran s jednim ili više R6;
R2 je aril, heteroaril, -C(=O)R5 ili -C(=O)OR5, gdje aril i heteroaril može svaki biti po izboru supstituiran s jednim ili više R6;
R5 je alkil, aril ili heteroaril, od kojih svaki može po izboru biti supstituiran s jednim ili više R6;
R6, svaki put kad se pojavljuje, je nezavisno izabran između alkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, -OCF3, -OCHF2, -OR10, -OH, -SH, -SR10, -C(=O)NR9R9, -NR9R9, -S(O)2NR9R9, -NR9S(O)2CF3, -C(=O)NR9S(O)2R9, -S(O)2NR9C(=O)OR9, -S(O)2NR9C(=O)NR9R9, -C(=O)NR9S(O)2CF3. -C(=O)R10, -NR9C(=O)H, -NR9C(=O)R10, -OC(=O)R10, -S(=O)R10, -S(O)2R10 i =O, gdje alkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R9a;
R8a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, arilalkil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2,- OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R14, -S(O)2NR14C(=O)OR14, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14 -S(O)2R14, =O, NR14C(=O)OR14 i -NR14S(O2)R14;
R9, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil i heterociklil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, heteroarilalkil i heterociklil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril, heteroarilalkil i heterociklil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R9a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R10, -S(O)2NR14C(=O)OR10, -S(O)2N14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14, =O i arilalkil;
R10, svaki put kad se pojavljuje, je nezavisno izabran između alkil, cikloalkil, aril, arilalkil, heteroaril i heterociklil, gdje cikloalkil, aril, arilalkil, heteroaril i heterociklil može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril i heterociklil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R10a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R9, -S(O)2NR14C(=O)OR9, -S(O)2NR14C(=O)NR14R14, -C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14 i arilalkil;
R14, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, aril, cikloalkil i heteroaril;
R21 je vodik, alkil, haloalkil, hidroksialkil, aril, halo, -CN, -C(=O)OH, -C(=O)OR10, -OR10, -C(=O)NR9R9 ili -C(=O)R10.
T1 i T2 su vodik;
T3 je vodik, alkil ili aril, gdje alkil ili aril mogu po izboru biti supstituirani s jednim ili više R6; i
T4 je vodik, alkil ili aril, gdje alkil ili aril mogu po izboru biti supstituirani s jednim ili više R6.
8. Spoj, enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, gdje:
Z je CH ili N;
R1 je aril, arilalkil ili heteroaril, od kojih bilo koji može biti po izboru supstituiran s jednim ili više R6;
R2 je aril, heteroaril ili -C(=O)OR5, gdje aril i heteroaril može svaki biti po izboru supstituiran s jednim ili više R6;
R5 je alkil, aril ili heteroaril, od kojih svaki može po izboru biti supstituiran s jednim ili više R6;
R6, svaki put kad se pojavljuje, je nezavisno izabran između alkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, -OCF3, -OCHF2, -OR10 -OH, -SH, -SR10, -C(=O)NR9R9, -NR9R9, -S(O)2NR9R9, -NR9S(O)2CF3, -C(=O)NR9S(O)2R9, -S(O)2NR9C(=O)OR9, -C(=O)R10, -NR9C(=O)H, -NR9C(=O)R10, -OC(=O)R10, -S(=O)R10, -S(O)2R10 i =O, gdje alkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R9a;
R8a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, arilalkil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R14, -S(O)2NR14C(=O)OR14, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14, =O, -NR14C(=O)OR14 i -NR14S(O2)R14;
R9, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, cikloalkil, aril, arilalkil, heteroaril i heterociklil, gdje alkil, cikloalkil, aril, arilalkil, heteroaril, i heterociklil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril i heterociklil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R9a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R10, -S(O)2NR14C (=O)OR10, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14, =O i arilalkil;
R10, svaki put kad se pojavljuje, je nezavisno izabran između alkil, cikloalkil, aril, heteroaril i heterociklil, gdje cikloalkil, aril, heteroaril i heterociklil može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril i heterociklil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R10a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R9, -S(O)2NR14C(=O)OR9, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14 i arilalkil;
R14, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, aril, cikloalkil i heteroaril;
R21 je vodik, alkil, haloalkil, hidroksialkil, aril, halo, -CN, -C(=O)OR10, -OR10, -C(=O)NR9R9 ili -C(=O)R10.
T1, T2 i T4 su vodik; i
T3 je vodik, alkil ili aril, gdje alkil ili aril mogu po izboru biti supstituirani s jednim ili više R6.
9. Spoj, enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, gdje:
Z je CH ili N;
R1 je aril, arilalkil ili heteroaril, od kojih bilo koji može biti po izboru supstituiran s jednim ili više R6;
R2 je heteroaril ili -C(=O)OR5, gdje heteroaril može po izboru biti supstituiran s jednim ili više R6;
R5 je alkil, aril ili heteroaril, od kojih svaki može po izboru biti supstituiran s jednim ili više R6;
R6, svaki put kad se pojavljuje, je nezavisno izabran između alkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, -OCF3, -OCHF2, -OR10, -OH, -SH, -SR10, -C(=O)NR9R9, -NR9R9, -S(O)2NR9R9, -NR9S(O)2CF3, -C(=O)R10, -NR9C(=O)H, -NR9C(=O)R10, -OC(=O)R10, -S(=O)R10, -S(O)2R10 i =O, gdje alkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-5 R9a;
R8a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, arilalkil, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14, =O, -NR14C(=O)OR14 i -NR14S(O2)R14;
R9, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, cikloalkil, aril, heteroaril i heterociklil, gdje alkil, cikloalkil, aril, heteroaril i heterociklil može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril i heterociklil svaki sadrži 1-4 heteroatoma izabrana između N, O i S;
R9a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14, =O i arilalkil;
R10, svaki put kad se pojavljuje, je nezavisno izabran između alkil, cikloalkil, aril i heteroaril, gdje cikloalkil, aril i heteroaril može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril sadrži 1-4 heteroatoma izabrana između N, O i S;
R10a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, cikloalkilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14 i arilalkil;
R14, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, aril, cikloalkil i heteroaril;
R21 je vodik, alkil, haloalkil, hidroksialkil, aril, halo, -CN, -C(=O)OR10, -C(=O)NR9R9 ili -C(=O)R10;
T1, T2 i T4 su vodik; i
T3 je vodik ili alkil, gdje alkil može po izboru biti supstituiran s jednim ili više R6.
10. Spoj, enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, gdje:
Z je CH ili N;
R1 je aril ili heteroaril, od kojih bilo koji može biti po izboru supstituiran s jednim ili više R6;
R2 je heteroaril ili -C(=O)OR5, gdje heteroaril može po izboru biti supstituiran s jednim ili više R6;
R5 je alkil, aril ili heteroaril, od kojih svaki može po izboru biti supstituiran s jednim ili više R6;
R6, svaki put kad se pojavljuje, je nezavisno izabran između alkil, aril, cikloalkil, heteroaril, heterociklil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, -OCF3, -OCHF2, -OR10, -OH, -SH, -SR10, -C(=O)NR9R9, -NR9R9, -S(O)2NR9R9, -NR9S(O)2CF3, -C(=O)R10, -NR9C(=O)H, -NR9C(=O)R10, -OC(=O)R10, -S(=O)R10, -S(O)2R10 i =O, gdje alkil, aril, cikloalkil, heteroaril, i heterociklil može svaki biti po izboru supstituiran s 0-5 R9a;
R8a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, arilalkil, cikloalkil, heteroaril, heterociklil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14, =O, -NR14C(=O)OR14 i -NR14S(O2)R14;
R9, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, cikloalkil, aril i heteroaril, gdje alkil, cikloalkil, aril i heteroaril, može svaki biti po izboru supstituiran s 0-5 R8a, i heteroaril sadrži 1-4 heteroatoma izabrana između N, O i S;
R9a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, heteroaril, heterociklil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR14, -NR14S(O2)R14, =O i arilalkil;
R10, svaki put kad se pojavljuje, je nezavisno izabran između alkil, cikloalkil, aril i heteroaril, gdje cikloalkil, aril i heteroaril može svaki biti po izboru supstituiran s 0-3 R10a, i heteroaril sadrži 1-4 heteroatoma izabrana između N, O i S;
R10a, svaki put kad se pojavljuje, je nezavisno izabran između alkil, haloalkil, aril, cikloalkil, heteroaril, heterociklil, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OCHF2, -OR14, -OH, -SH, -SR14, -C(=O)NR14R14, -NR14R14, -S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -S(=O)R14, -S(O)2R14,-NR14C(=O)OR14, -NR14S(O2)R14 i arilalkil;
R14, svaki put kad se pojavljuje, je nezavisno izabran između vodik, alkil, aril, cikloalkil i heteroaril;
R21 je vodik, alkil, haloalkil, hidroksialkil, aril, halo, -CN, -C(=O)OR10 ili -C(=O)NR9R9.
T1, T2 i T4 su vodik; i
T3 je vodik ili alkil.
11. Spoj prema zahtjevu 1, gdje se spoj izabire između jednog od:
trans-tert-Butil-2-metil-4-(1-(4-(metilsulfonil)fenil)-2-okso-1,2-dihidropiridin-4-iloksi)piperidin-1-karboksilat;
cis-tert-Butil-2-metil-4-(1-(4-(metilsulfonil)fenil)-2-okso-1,2-dihidropiridin-4-iloksi)piperidin-1-karboksilat;
cis-4-(2-Metil-1-(5-propilpirimidin-2-il)piperidin-4-iloksi)-1-(4-(metilsulfonil)fenil)piridin-2(1H)-on, TFA sol;
trans-4-(2-Metil-1-(5-propilpirimidin-2-il)piperidin-4-iloksi)-1-(4-(metilsulfonil)fenil)piridin-2(1H)-on, TFA sol;
1-(2-Metilbenzo[d]oksazol-5-il)-4-(1-(5-propilpirimidin-2-il)piperidin-4-iloksi)piridin-2(1H)-on;
1-(2-Izopropilbenzo[d]oksazol-5-il)-4-(1-(5-propilpirimidin-2-il)piperidin-4-iloksi)piridin-2(1H)-on;
1-(2-Metilbenzo[d]oksazol-6-il)-4-(1-(5-propilpirimidin-2-il)piperidin-4-iloksi)piridin-2(1H)-on, klorovodična sol;
tert-Butil-4-(1-(4-(metilsulfonil)fenil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
2-(4-(Metilsulfonil)fenil)-5-(1-(5-propilpirimidin-2-il)piperidin-4-iloksi)piridazin-3(2H)-on;
5-(1-(5-Ciklopropilpirimidin-2-il)piperidin-4-iloksi)-2-(4-(metilsulfonil)fenil)piridazin-3(2H)-on;
5-(1-(5-Acetilpirimidin-2-il)piperidin-4-iloksi)-2-(4-(metilsulfonil)fenil)piridazin-3(2H)-on;
5-(1-(5-Etilpirimidin-2-il)piperidin-4-iloksi)-2-(4-(metilsulfonil)fenil)piridazin-3(2H)-on;
tert-Butil-4-(1-(4-metoksibenzil)-6-okso-3-fenil-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
Metil-4-(1-(tert-butoksikarbonil)piperidin-4-iloksi)-1-(3,4-diklorofenil)-6-okso-1,6-dihidropiridazin-3-karboksilat;
tert-Butil-4-(1-(3,4-diklorofenil)-3-(metilkarbamoil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
tert-Butil-4-(3-karbamoil-1-(3,4-diklorofenil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
tert-Butil-4-(1-(3,4-diklorofenil)-3-(hidroksimetil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
Metil-4-(1-(tert-butoksikarbonil)piperidin-4-iloksi)-1-(4-(metilsu(fonil)fenil)-6-okso-1,6-dihidropiridazin-3-karboksilat;
tert-Butil-4-(1-(4-metoksibenzil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
tert-Butil-4-(3-cijano-1-(3,4-diklorofenil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
4-(1-(5-Ciklopropilpirimidin-2-il)piperidin-4-iloksi)-1-(3,4-diklorofenil)-6-okso-1,6-dihidropiridazin-3-karbonitril;
1-(3,4-Diklorofenil)-6-okso-4-(1-(5-propilpirimidin-2-il)piperidin-4-iloksi)-1,6-dihidropiridazin-3-karbonitril;
4-(1-(5-Kloropirimidin-2-il)piperidin-4-iloksi)-1-(3,4-diklorofenil)-6-okso-1,6-dihidropiridazin-3-karbonitril;
1-(3,4-Diklorofenil)-4-(1-(5-jodopirimidin-2-il)piperidin-4-iloksi)-6-okso-1,6-dihidropiridazin-3-karbonitril;
tert-Butil-4-(3-amino-1-(3,4-diklorofenil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
1-(3,4-Diklorofenil)-6-okso-4-(1-(5-(trifluorometil)pirimidin-2-il)piperidin-4-iloksi)-1,6-dihidropiridazin-3-karbonitril;
tert-Butil-4-(3-kloro-1-(3,4-diklorofenil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
2-(3,4-Diklorofenil)-5-(1-(5-propilpirimidin-2-il) piperidin-4-iloksi) piridazin-3(2H)-on;
Metil-4-(1-(tert-butoksikarbonil)piperidin-4-iloksi)-1-(4-cijano-3-fluorofenil)-6-okso-1,6-dihidropiridazin-3-karboksilat;
Metil-4-(1-(tert-butoksikarbonil)piperidin-4-iloksi)-1-(6-cijanopiridin-3-il)-6-okso-1,6-dihidropiridazin-3-karboksilat;
tert-Butil-4-(3-cijano-1-(4-(metilsulfonil)fenil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
Metil-1-(4-cijano-3-fluorofenil)-6-okso-4-(1-(5-propilpirimidin-2-il)piperidin-4-iloksi)-1,6-dihidropiridazin-3-karboksilat;
Metil-1-(4-cijano-3-fluorofenil)-4-(1-(5-ciklopropilpirimidin-2-il)piperidin-4-iloksi)-6-okso-1,6-dihidropiridazin-3-karboksilat;
tert-Butil-4-(3-cijano-1-(4-cijano-3-fluorofenil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
tert-Butil-4-(3-cijano-1-(6-cijanopiridin-3-il)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
1-(4-Cijano-3-fluorofenil)-4-(1-(5-jodopirimidin-2-il)piperidin-4-iloksi)-6-okso-1,6-dihidropiridazin-3-karbonitril;
1-(6-Cijanopiridin-3-il)-4-(1-(5-jodopirimidin-2-il) piperidin-4-iloksi)-6-okso-1,6-dihidropiridazin-3-karbonitril;
1-(4-Cijano-3-fluorofenil)-6-okso-4-(1-(5-propilpirimidin-2-il)piperidin-4-iloksi)-1,6-dihidropiridazin-3-karbonitril;
1-(4-Cijano-3-fluorofenil)-6-okso-4-(1-(5-(trifluorometil)pirimidin-2-il)piperidin-4-iloksi)-1,6-dihidropiridazin-3-karbonitril;
1-(6-Cijanopiridin-3-il)-6-okso-4-(1-(5-(trifluorometil)pirimidin-2-il)piperidin-4-iloksi)-1,6-dihidropiridazin-3-karbonitril;
4-(1-(5-Bromopirimidin-2-il)piperidin-4-iloksi)-1-(4-cijano-3-fluorofenil)-6-okso-1,6-dihidropiridazin-3-karbonitril;
Metil-4-(1-(5-bromopirimidin-2-il)piperidin-4-iloksi)-1-(4-cijano-3-fluorofenil)-6-okso-1,6-dihidropiridazin-3-karboksilat;
Metil-1-(4-bromo-3-fluorofenil)-4-(1-(tert-butoksikarbonil)piperidin-4-iloksi)-6-okso-1,6-dihidropiridazin-3-karboksilat;
Metil-1-(4-bromo-2-fluorofenil)-4-(1-(tert-butoksikarbonil)piperidin-4-iloksi)-6-okso-1,6-dihidropiridazin-3-karboksilat;
tert-Butil-4-(1-(4-bromo-3-fluorofenil)-3-cijano-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
tert-Butil-4-(1-(4-bromo-2-fluorofenil)-3-cijano-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
4-(1-(5-Kloropirimidin-2-il)piperidin-4-iloksi)-1-(4-(metilsulfonil)fenil)-6-okso-1,6-dihidropiridazin-3-karbonitril;
4-(1-(5-Jodopirimidin-2-il)piperidin-4-iloksi)-1-(4-(metilsulfonil)fenil)-6-okso-1,6-dihidropiridazin-3-karbonitril;
1-(4-(Metilsulfonil)fenil)-6-okso-4-(1-(5-(trifluorometil)pirimidin-2-il)piperidin-4-iloksi)-1,6-dihidropiridazin-3-karbonitril;
6-(Hidroksimetil)-5-(1-(5-kloropirimidin-2-il)piperidin-4-iloksi)-2-(4-(metilsulfonil)fenil)piridazin-3(2H)-on;
6-(Hidroksimetil)-5-(1-(5-jodopirimidin-2-il)piperidin-4-iloksi)-2-(4-(metilsulfonil)fenil)piridazin-3(2H)-on;
4-(1-(5-Cijanopirimidin-2-il)piperidin-4-iloksi)-1-(4-(metilsulfonil)fenil)-6-okso-1,6-dihidropiridazin-3-karbonitril;
1-(4-Bromo-3-fluorofenil)-4-(1-(5-kloropirimidin-2-il)piperidin-4-iloksi)-6-okso-1,6-dihidropiridazin-3-karbonitril;
1-(4-Bromo-2-fluorofenil)-4-(1-(5-kloropirimidin-2-il)piperidin-4-iloksi)-6-okso-1,6-dihidropiridazin-3-karbonitril;
tert-Butil-4-(1-(4-cijano-3-fluorofenil)-3-(hidroksimetil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
tert-Butil-4-(3-cijano-1-(4-nitrofenil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
4-(1-(5-(Difluorometoksi)pirimidin-2-il)piperidin-4-iloksi)-1-(4-(metilsulfonil)fenil)-6-okso-1,6-dihidropiridazin-3-karbonitril;
Izopropil-4-(3-cijano-1-(4-cijano-3-fluorofenil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
Izopropil-4-(3-cijano-1-(4-(metilsulfonil)fenil)-6-okso-1,6-dihidropiridazin-4-iloksi)piperidin-1-karboksilat;
trans-tert-Butil-4-(5-kloro-1-(4-cijano-3-fluorofenil)-2-okso-1,2-dihidropiridin-4-iloksi)-3-metilpiperidin-1-karboksilat; i
Cis- i trans-izomeri 4-(5-kloro-4-(1-(5-ciklopropilpirimidin-2-il)-3-metilpiperidin-4-iloksi)-2-oksopiridin-(2H)-il)-2-fluorobenzonitrila.
12. Farmaceutska smjesa koja se sastoji od terapijski učinkovite količine spoja prema bilo kojem od zahtjeva 1 do 11, ili enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, i po izboru farmaceutski prihvatljivi nosač.
13. Farmaceutska smjesa prema zahtjevu 12, koja dalje sadrži terapijski učinkovitu količinu jednog ili više drugih terapijski aktivnih tvari.
14. Spoj prema bilo kojem od zahtjeva 1 do 11, ili enantiomer, diastereomer, ili njegova farmaceutski prihvatljiva sol, i po izboru dodatno terapijsko sredstvo, za uporabu u prevenciji, inhibiciji ili liječenju napredovanja ili početka bolesti ili poremećaja povezanih s aktivnošću GPR 119 G protein-vezanog receptora gdje:
(a) bolesti ili poremećaji se izabiru iz grupe koja obuhvaća dijabetes, hiperglikemiju, poremećaj tolerancije glukoze, inzulinsku rezistenciju, hiperinzulinemiju, retinopatiju, neuropatiju, nefropatiju, produljeno zacjeljivanje rana, aterosklerozu i njezin nastavak, poremećaj funkcije srca, ishemiju miokarda, moždani udar, metabolički sindrom, hipertenziju, pretilost, dislipidemiju, hiperlipidemiju, hipertrigliceridemiju, hiperkolesterolemiju, niski HDL, visoki LDL, ne-srčanu ishemiju, infekciju, rak, vaskularnu restenozu, pankreatitis, neurodegenerativnu bolest, poremećaje lipida, kognitivni poremećaj i demenciju, bolest kostiju, lipodistrofiju povezanu s proteazom HIV-a te glaukom; i
(b) dodatno terapijsko sredstvo se izabire iz grupe koja obuhvaća antidijabetike, antihiperglikemijska sredstva, sredstva protiv hiperinzulinemije, sredstva protiv retinopatije, sredstva protiv neuropatije, sredstva protiv nefropatije, sredstva protiv ateroskleroze, sredstva protiv ishemije, sredstva protiv hipertenzije, sredstva protiv pretilosti, sredstva protiv dislipidemije, sredstva protiv hiperlipidemije, sredstva protiv hipertrigliceridemije, sredstva protiv hiperkolesterolemije, sredstva protiv restenoze, sredstva protiv pankreatitisa, sredstva protiv neurodegenerativne bolesti, sredstva protiv poremećaja lipida, sredstva za snižavanje lipida, sredstva za suzbijanje apetita, lijekove za zatajenje srca, lijekove za periferne arterijske bolesti i sredstva protiv upale.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8105808P | 2008-07-16 | 2008-07-16 | |
US8106908P | 2008-07-16 | 2008-07-16 | |
US8106008P | 2008-07-16 | 2008-07-16 | |
PCT/US2009/050618 WO2010009183A1 (en) | 2008-07-16 | 2009-07-15 | Pyridone and pyridazone analogues as gpr119 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20130120T1 true HRP20130120T1 (hr) | 2013-03-31 |
Family
ID=41137417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130120AT HRP20130120T1 (hr) | 2008-07-16 | 2013-02-11 | Analozi piridona i piridazona kao gpr119 modulatori |
Country Status (19)
Country | Link |
---|---|
US (2) | US8372837B2 (hr) |
EP (1) | EP2313395B1 (hr) |
JP (1) | JP2011528362A (hr) |
CN (1) | CN102159566A (hr) |
AR (1) | AR073254A1 (hr) |
BR (1) | BRPI0915918A2 (hr) |
CA (1) | CA2730929A1 (hr) |
CY (1) | CY1113715T1 (hr) |
DK (1) | DK2313395T3 (hr) |
EA (1) | EA018268B1 (hr) |
ES (1) | ES2400587T3 (hr) |
HR (1) | HRP20130120T1 (hr) |
MX (1) | MX2011000394A (hr) |
PL (1) | PL2313395T3 (hr) |
PT (1) | PT2313395E (hr) |
SI (1) | SI2313395T1 (hr) |
SM (1) | SMT201300040B (hr) |
TW (1) | TW201006821A (hr) |
WO (1) | WO2010009183A1 (hr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
AU2010264720A1 (en) | 2009-06-24 | 2011-12-08 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
WO2010149685A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
WO2011030139A1 (en) | 2009-09-11 | 2011-03-17 | Astrazeneca Ab | 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
MX2012011460A (es) * | 2010-04-08 | 2012-11-23 | Squibb Bristol Myers Co | Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119. |
MX2012012902A (es) | 2010-05-06 | 2012-12-17 | Bristol Myers Squibb Co | Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119. |
US8729084B2 (en) | 2010-05-06 | 2014-05-20 | Bristol-Myers Squibb Company | Benzofuranyl analogues as GPR119 modulators |
MX2012013465A (es) | 2010-05-17 | 2013-12-02 | Array Biopharma Inc | Lactamas sustituidas con piperidinilo como moduladores de gpr119. |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
KR101563793B1 (ko) | 2010-10-08 | 2015-10-27 | 카딜라 핼쓰캐어 리미티드 | 신규한 gpr 119 작용물질 |
AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013173198A1 (en) | 2012-05-16 | 2013-11-21 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators |
CN104780915A (zh) | 2012-07-11 | 2015-07-15 | 埃尔舍利克斯治疗公司 | 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物 |
AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
CN103664795B (zh) * | 2012-09-06 | 2017-10-03 | 华东理工大学 | 哒嗪酮类化合物及其用途 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
KR102072268B1 (ko) * | 2013-03-13 | 2020-01-31 | 추가이 세이야쿠 가부시키가이샤 | 디하이드로피리다진-3,5-디온 유도체 |
US9499553B2 (en) | 2013-03-13 | 2016-11-22 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same |
US9751039B2 (en) | 2013-04-18 | 2017-09-05 | Climeworks Ag | Low-pressure drop structure of particle adsorbent bed for adsorption gas separation process |
WO2014175621A1 (en) * | 2013-04-25 | 2014-10-30 | Yuhan Corporation | Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same |
WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
CN104370806B (zh) * | 2014-06-17 | 2017-07-07 | 中国海洋大学 | 一种吡啶酮生物碱类化合物及其制备方法和用途 |
IL277495B1 (en) * | 2018-03-23 | 2024-04-01 | Carmot Therapeutics Inc | Modulators of protein-coupled receptors - G |
BR112021005793A2 (pt) | 2018-09-27 | 2021-06-29 | Fmc Corporation | composto e processos para preparar um composto |
CN110845426A (zh) * | 2019-11-29 | 2020-02-28 | 都创(上海)医药科技有限公司 | 一种2-氯-5-氰基嘧啶化合物制备方法 |
CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3826643A (en) | 1967-08-07 | 1974-07-30 | American Cyanamid Co | Method of controlling undesirable plant species using 3-nitropyridines |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US6566384B1 (en) | 1996-08-07 | 2003-05-20 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
AU767456B2 (en) | 1998-07-06 | 2003-11-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
CA2320730A1 (en) | 1998-12-23 | 2000-07-06 | Renhua Li | Thrombin or factor xa inhibitors |
WO2002002519A2 (en) | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | THROMBIN OR FACTOR Xa INHIBITORS |
AU2002218509A1 (en) | 2000-12-01 | 2002-06-11 | Yamanouchi Pharmaceutical Co..Ltd. | Method of screening remedy for diabetes |
CA2469435A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
US6921821B2 (en) * | 2002-06-12 | 2005-07-26 | Abbott Laboratories | Antagonists of melanin concentrating hormone receptor |
DK1599468T3 (da) | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
CN1751038A (zh) | 2003-02-24 | 2006-03-22 | 艾尼纳制药公司 | 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗 |
SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
CN100509798C (zh) * | 2003-07-11 | 2009-07-08 | 艾尼纳制药公司 | 作为新陈代谢调节剂的三取代芳基和杂芳基衍生物以及预防和治疗与其相关之病症 |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
EP2287166A3 (en) * | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
CN1829718A (zh) * | 2003-07-14 | 2006-09-06 | 艾尼纳制药公司 | 作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症 |
US20070088163A1 (en) | 2003-09-12 | 2007-04-19 | Kemia, Inc. | Modulators of calcitonin and amylin activity |
WO2005089786A2 (en) | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
SI1756096T1 (sl) | 2004-05-03 | 2009-10-31 | Hoffmann La Roche | Indolilni derivati kot modulatorji jetrnega x receptorja |
DK1756084T3 (da) * | 2004-06-04 | 2009-03-23 | Arena Pharm Inc | Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed |
US8193359B2 (en) | 2004-12-24 | 2012-06-05 | Prosidion Limited | G-protein coupled receptor agonists |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
EP1893246A4 (en) | 2005-06-23 | 2009-05-06 | Univ Emory | STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGUE FOR TUMOR IMAGING |
EP1907384A2 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
TW200738682A (en) * | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
AR059898A1 (es) * | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
WO2008025799A1 (en) * | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridazine compounds for treating gpr119 related disorders |
PE20090222A1 (es) * | 2007-05-04 | 2009-03-27 | Bristol Myers Squibb Co | Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119 |
PE20090449A1 (es) * | 2007-07-17 | 2009-04-18 | Bristol Myers Squibb Co | Agonistas de receptor acoplado a proteina g gpr119 de piridona |
EP2374805A4 (en) * | 2008-12-25 | 2012-06-27 | Nissan Chemical Ind Ltd | PYRIDAZINE-3 (2H) -ONE HYDROCHLORIDE COMPOUND CRYSTALS AND METHOD FOR THE PRODUCTION THEREOF |
MX2012011460A (es) * | 2010-04-08 | 2012-11-23 | Squibb Bristol Myers Co | Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119. |
-
2009
- 2009-07-10 TW TW098123477A patent/TW201006821A/zh unknown
- 2009-07-15 CA CA2730929A patent/CA2730929A1/en not_active Abandoned
- 2009-07-15 ES ES09790426T patent/ES2400587T3/es active Active
- 2009-07-15 EA EA201100210A patent/EA018268B1/ru not_active IP Right Cessation
- 2009-07-15 JP JP2011518862A patent/JP2011528362A/ja active Pending
- 2009-07-15 CN CN2009801362083A patent/CN102159566A/zh active Pending
- 2009-07-15 BR BRPI0915918A patent/BRPI0915918A2/pt not_active IP Right Cessation
- 2009-07-15 DK DK09790426.2T patent/DK2313395T3/da active
- 2009-07-15 SI SI200930537T patent/SI2313395T1/sl unknown
- 2009-07-15 WO PCT/US2009/050618 patent/WO2010009183A1/en active Application Filing
- 2009-07-15 AR ARP090102687A patent/AR073254A1/es not_active Application Discontinuation
- 2009-07-15 PT PT97904262T patent/PT2313395E/pt unknown
- 2009-07-15 MX MX2011000394A patent/MX2011000394A/es active IP Right Grant
- 2009-07-15 US US13/003,914 patent/US8372837B2/en active Active
- 2009-07-15 PL PL09790426T patent/PL2313395T3/pl unknown
- 2009-07-15 EP EP09790426A patent/EP2313395B1/en not_active Not-in-force
-
2013
- 2013-01-18 US US13/744,604 patent/US20130131074A1/en not_active Abandoned
- 2013-02-11 HR HRP20130120AT patent/HRP20130120T1/hr unknown
- 2013-02-22 CY CY20131100168T patent/CY1113715T1/el unknown
- 2013-04-03 SM SM201300040T patent/SMT201300040B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PL2313395T3 (pl) | 2013-05-31 |
US8372837B2 (en) | 2013-02-12 |
JP2011528362A (ja) | 2011-11-17 |
DK2313395T3 (da) | 2013-03-18 |
TW201006821A (en) | 2010-02-16 |
EP2313395A1 (en) | 2011-04-27 |
US20130131074A1 (en) | 2013-05-23 |
CN102159566A (zh) | 2011-08-17 |
AR073254A1 (es) | 2010-10-28 |
ES2400587T3 (es) | 2013-04-10 |
PT2313395E (pt) | 2013-03-07 |
BRPI0915918A2 (pt) | 2018-07-10 |
CA2730929A1 (en) | 2010-01-21 |
MX2011000394A (es) | 2011-03-01 |
EP2313395B1 (en) | 2012-12-19 |
CY1113715T1 (el) | 2016-06-22 |
EA018268B1 (ru) | 2013-06-28 |
WO2010009183A1 (en) | 2010-01-21 |
US20110263548A1 (en) | 2011-10-27 |
SMT201300040B (it) | 2013-05-06 |
EA201100210A1 (ru) | 2011-08-30 |
SI2313395T1 (sl) | 2013-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130120T1 (hr) | Analozi piridona i piridazona kao gpr119 modulatori | |
JP7037500B2 (ja) | Mdm2タンパク質分解剤 | |
JP6542212B2 (ja) | ブロモドメイン阻害剤としての新規キナゾリノン | |
TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
JP5966014B2 (ja) | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用 | |
EP2255848A2 (en) | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer | |
HRP20120115T1 (hr) | Derivati azabifenil aminobenzojeve kiseline kao inhibitori dhodh | |
JP2007510689A5 (hr) | ||
JP2020521740A5 (hr) | ||
CA2542105A1 (en) | Compounds and compositions as protein kinase inhibitors | |
JP2007519754A5 (hr) | ||
HRP20170357T1 (hr) | Sastavi i postupci za liječenje poremećaja zbog konzumacije alkohola, bolova i ostalih bolesti | |
JP2015083583A (ja) | mGluR1−およびmGluR5−アンタゴニスト活性を有するベンゾアゾリルピペラジン誘導体 | |
KR20070034524A (ko) | 무스카린 수용체 조정자 | |
JP2018502877A5 (hr) | ||
RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
JP2016507496A (ja) | ブロモドメイン阻害剤としての新規複素環式化合物 | |
NZ590602A (en) | Pyrimidine derivatives as kinase inhibitors | |
CA2469821A1 (en) | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
CA2642922A1 (en) | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | |
JP2010519275A (ja) | セリンプロテアーゼ阻害剤としての式(i)の化合物 | |
JP2017516830A (ja) | ピラゾール化合物及びt型カルシウムチャンネルブロッカーとしてのそれらの使用 | |
CA2551529A1 (en) | Amide derivative and medicine |